Advances in therapeutics and vaccines for Marburg virus disease: challenges and future directions
Expert Review of Anti-infective Therapy·
- DOI
- 10.1080/14787210.2026.2723576
- PMID
- 42636264
- PMCID
- —
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Informa UK Limited
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article is relevant to public health because Marburg virus disease is described as highly lethal and lacking approved virus-specific interventions. The abstract frames future needs around licensed field-ready tools, diagnostics, trial designs, combination therapies, research equity, and cross-border One Health surveillance infrastructure.
Structured evidence summary
Research question
The article addresses progress and remaining challenges in developing vaccines and therapeutics for Marburg virus disease, including research productivity and collaboration patterns relevant to those interventions.
Study design
The abstract describes a hybrid approach that combined broad bibliometric analysis with a focused qualitative narrative review.
Population and setting
The disease focus is Marburg virus disease. The abstract discusses evidence from non-human primate studies, early clinical and preclinical vaccine work, and research output patterns involving high-income countries and endemic African countries.
Main findings
The abstract reports that MR191N protected non-human primates after exposure, and that RNA-targeted approaches and galidesivir showed strong preclinical activity against viral replication. It also reports that several vaccine platforms are in early clinical or preclinical evaluation, and that publication and collaboration patterns are geographically uneven, with the United States contributing 31.7% of output while endemic African countries are underrepresented.
Public-health relevance
The article is relevant to public health because Marburg virus disease is described as highly lethal and lacking approved virus-specific interventions. The abstract frames future needs around licensed field-ready tools, diagnostics, trial designs, combination therapies, research equity, and cross-border One Health surveillance infrastructure.
Important limitations
The abstract indicates that much of the intervention evidence discussed remains preclinical or early-phase, and that no virus-specific intervention has yet been approved. This summary is limited to the supplied single-article abstract and metadata; the full article would be needed for decision-grade assessment.
GIDS interpretation
This paper is discoverable as a peer-reviewed journal article on Marburg virus disease, with classifier linkage to that disease and a focus on vaccines, therapeutics, and research-system context. It should be interpreted as contextual literature for editorial review, not as confirmation of any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 4 auditable classifier relationships to diseases, places, topics, and study design.